The first was the MC3-LNP, also known as Onpattro, a first-ever siRNA therapeutic developed by Alnylam pharmaceuticals for the treatment of transthyretin (TTR) amyloidosis [58,59]. This evidence concerns the gene TTR and amyloidosis.